# Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

> **NCT06084481** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 302 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancers
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Head and Neck Squamous-Cell Carcinoma
- Platinum Resistant High Grade Epithelial Ovarian Cancer

## Interventions

- **DRUG:** ABBV-400
- **DRUG:** Itraconazole (ITZ)

## Key facts

- **NCT ID:** NCT06084481
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-09
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06084481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06084481, "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06084481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*